Generic Name and Formulations:
Memantine HCl 5mg, 10mg; tabs.
Indications for NAMENDA:
Moderate-to-severe dementia of the Alzheimer's type.
Initially 5mg once daily; titrate at intervals of at least 1 week to 5mg twice daily, then to 5mg and 10mg as separate doses, then to 10mg twice daily (prescribe Titration Pak for 1st 4 weeks). Severe renal impairment (CrCl 5–29mL/min): titrate to max 5mg twice daily.
Severe hepatic impairment. Alkalinized urine (eg, renal tubular acidosis, severe UTI) increases memantine serum levels. Seizure disorder. Pregnancy (Cat.B). Nursing mothers.
Caution with other NMDA antagonists (eg, amantadine, ketamine, dextromethorphan). May affect or be affected by renally-excreted drugs (eg, triamterene, HCTZ, metformin, cimetidine, nicotine, ranitidine, quinidine). Plasma levels may be increased by urinary alkalinizers.
NMDA receptor antagonist.
Headache, dizziness, confusion, diarrhea, constipation, hypertension, pain, somnolence, hallucination, urinary disorders, dyspnea.
Tabs (YES); Oral soln, XR caps (NO)
Tabs—60; Titration Pak (28 x 5mg + 21 x 10mg)—1; Oral soln—360mL; XR caps 7mg, 21mg—30; 14mg, 28mg—30, 90; XR Titration Pak (7 x 7mg + 7 x 14mg + 7 x 21mg + 7 x 28mg)—1
Neurology Advisor Articles
- Clarifying Cardiovascular Risk in Migraine
- Parkinson Disease Symptom Fluctuations Well-Managed With Adaptive Deep Brain Stimulation
- More Evidence Supports Benefits of Cannabidiol for Treatment-Resistant Epilepsy
- Monthly Erenumab Reduces Frequency of Episodic Migraine
- Female Gender, Natalizumab Exposure Associated With Increased Lymphopenia Risk in FNG-Treated MS
- Tamsulosin Associated With Dementia Risk in Older Patients With BPH
- FDA Approves Blood Test to Assess Concussion
- Gait Difficulty in Parkinson Disease May Be Associated With More Progressive Disease Course
- Tau PET a Useful Biomarker for Alzheimer Disease Risk and Progression
- Multiple Sclerosis Drug Zinbryta Withdrawn From the Market
- Undifferentiated Headaches Common in Children, Adolescents
- Smoking Associated With Increased Relapse Rate in Interferon Beta-Treated Relapsing-Remitting MS
- Frontotemporal Dementia, Frontotemporal Lobar Degeneration Symptoms More Common Later in Life
- No Reduction in Cerebral Perfusion With Intensive Blood Pressure Lowering
- Successful Delirium Prevention in Critically Ill With Dexmedetomidine